76 related articles for article (PubMed ID: 22564734)
41. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system.
Caporali S; Falcinelli S; Starace G; Russo MT; Bonmassar E; Jiricny J; D'Atri S
Mol Pharmacol; 2004 Sep; 66(3):478-91. PubMed ID: 15322239
[TBL] [Abstract][Full Text] [Related]
42. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma.
Xia L; Huang W; Tian D; Zhu H; Zhang Y; Hu H; Fan D; Nie Y; Wu K
J Hepatol; 2012 Sep; 57(3):600-12. PubMed ID: 22613004
[TBL] [Abstract][Full Text] [Related]
43. Flavonoids as potential anti-hepatocellular carcinoma agents: recent approaches using HepG2 cell line.
Xia JF; Gao JJ; Inagaki Y; Kokudo N; Nakata M; Tang W
Drug Discov Ther; 2013 Feb; 7(1):1-8. PubMed ID: 23524937
[TBL] [Abstract][Full Text] [Related]
44. ATP-based cell viability assay is superior to trypan blue exclusion and XTT assay in measuring cytotoxicity of anticancer drugs Taxol and Imatinib, and proteasome inhibitor MG-132 on human hepatoma cell line HepG2.
Nowak E; Kammerer S; Küpper JH
Clin Hemorheol Microcirc; 2018; 69(1-2):327-336. PubMed ID: 29630545
[TBL] [Abstract][Full Text] [Related]
45. CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma.
Chan CY; Chiu DK; Yuen VW; Law CT; Wong BP; Thu KL; Cescon DW; Soria-Bretones I; Cheu JW; Lee D; Tse AP; Zhang MS; Tan KV; Ng IO; Khong PL; Yau TC; Bray MR; Mak TW; Wong CC
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2119514119. PubMed ID: 35914158
[TBL] [Abstract][Full Text] [Related]
46. Shadows in the current management of hepatocellular carcinoma in Spain - An embarrassing truth.
Crespo J; Andrade RJ
Rev Esp Enferm Dig; 2019 Oct; 111(10):727-730. PubMed ID: 31566408
[TBL] [Abstract][Full Text] [Related]
47. Hepatitis B Virus Infection Dampens CtIP Expression in Hepatoma Cell.
Zhang D; Liu H; Lin J; Ye D
J Cancer; 2018; 9(7):1182-1187. PubMed ID: 29675099
[TBL] [Abstract][Full Text] [Related]
48. Enhancing the efficacy of hepatocellular carcinoma chemotherapeutics with natural anticancer agents.
Alisi A; Balsano C
Nutr Rev; 2007 Dec; 65(12 Pt 1):550-3. PubMed ID: 18236694
[TBL] [Abstract][Full Text] [Related]
49. ATR Inhibitors and Paclitaxel in Melanoma.
Ashworth A
Clin Cancer Res; 2021 Sep; 27(17):4667-4668. PubMed ID: 34172499
[TBL] [Abstract][Full Text] [Related]
50. Chromosomal instability in HCC: a key function for checkpoint kinase 2.
Eferl R; Trauner M
Gut; 2018 Feb; 67(2):204-205. PubMed ID: 28476916
[No Abstract] [Full Text] [Related]
51. Synthesis, growth inhibitory activity against tumor cells and structure-activity relationship of CGK733 and its analogs.
Inagaki Y; Hashimoto K; Wakamori S; Katsuta R; Yajima A; Kaida D; Ishigami K
Biosci Biotechnol Biochem; 2024 Apr; ():. PubMed ID: 38678003
[TBL] [Abstract][Full Text] [Related]
52. Rare Genetic Diseases with Defects in DNA Repair: Opportunities and Challenges in Orphan Drug Development for Targeted Cancer Therapy.
Bhattacharjee S; Nandi S
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30200453
[TBL] [Abstract][Full Text] [Related]
53. Reducing protein regulator of cytokinesis 1 as a prospective therapy for hepatocellular carcinoma.
Liu X; Li Y; Meng L; Liu XY; Peng A; Chen Y; Liu C; Chen H; Sun S; Miao X; Zhang Y; Zheng L; Huang K
Cell Death Dis; 2018 May; 9(5):534. PubMed ID: 29748662
[TBL] [Abstract][Full Text] [Related]
54. Substituted Tetrahydroisoquinolines as Microtubule-destabilizing Agents in Triple Negative Human Breast Cancer Cells.
Gangapuram M; Jean R; Mazzio E; Badisa R; Eyunni S; Goodman CB; Redda KK; Soliman KF
Anticancer Res; 2016 Oct; 36(10):5043-5052. PubMed ID: 27798863
[TBL] [Abstract][Full Text] [Related]
55. PERK/CHOP contributes to the CGK733-induced vesicular calcium sequestration which is accompanied by non-apoptotic cell death.
Wang Y; Kuramitsu Y; Baron B; Kitagawa T; Akada J; Tokuda K; Cui D; Nakamura K
Oncotarget; 2015 Sep; 6(28):25252-65. PubMed ID: 26259235
[TBL] [Abstract][Full Text] [Related]
56. A new arylbenzofuran derivative functions as an anti-tumour agent by inducing DNA damage and inhibiting PARP activity.
Chen H; Zeng X; Gao C; Ming P; Zhang J; Guo C; Zhou L; Lu Y; Wang L; Huang L; He X; Mei L
Sci Rep; 2015 Jun; 5():10893. PubMed ID: 26041102
[TBL] [Abstract][Full Text] [Related]
57. Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma.
Weng MT; Tung TH; Lee JH; Wei SC; Lin HL; Huang YJ; Wong JM; Luo J; Sheu JC
Sci Rep; 2015 Apr; 5():9357. PubMed ID: 25880358
[TBL] [Abstract][Full Text] [Related]
58. Involvement of DNA damage response pathways in hepatocellular carcinoma.
Yang SF; Chang CW; Wei RJ; Shiue YL; Wang SN; Yeh YT
Biomed Res Int; 2014; 2014():153867. PubMed ID: 24877058
[TBL] [Abstract][Full Text] [Related]
59. CGK733 enhances multinucleated cell formation and cytotoxicity induced by taxol in Chk1-deficient HBV-positive hepatocellular carcinoma cells.
Wang H; Zuo B; Wang H; Ren L; Yang P; Zeng M; Duan D; Liu C; Li M
Biochem Biophys Res Commun; 2012 May; 422(1):103-8. PubMed ID: 22564734
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
